# CENTOGENE GmbH Rostock clinical trials: 57 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 57 trials with CENTOGENE GmbH Rostock as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by CENTOGENE GmbH Rostock: 57 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/centogene-gmbh-rostock

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 57
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 57, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 15, 2023 | NCT06040008 | Investigating the Impact of Environmental Factors on the Transcriptomics Profile in Healthy Individuals | CENTOGENE GmbH Rostock | Observational | Completed | Healthy Volunteers | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06040008) |
| September 2, 2022 | NCT05526664 | Omics Gaucher Study: Multiomic Approach | CENTOGENE GmbH Rostock | Observational | Unknown | Gaucher Disease | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05526664) |
| October 12, 2021 | NCT05075187 | Epidemiological Study in FRONtoTemporal Dementia | CENTOGENE GmbH Rostock | Observational | Completed | Frontotemporal Dementia | 2,287 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05075187) |
| June 14, 2021 | NCT04925804 | Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) | CENTOGENE GmbH Rostock | Observational | Completed | Hypophosphatasia | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04925804) |
| September 16, 2020 | NCT04548921 | Biomarker for Friedreich's Ataxia (BioFridA) | CENTOGENE GmbH Rostock | Observational | Unknown | FXN Gene, FRDA, Hereditary Diseases | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04548921) |
| April 22, 2020 | NCT04357496 | COVID-19 Epidemic Response Study | CENTOGENE GmbH Rostock | Observational | Withdrawn | Fever, Pneumonia, Cough | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04357496) |
| September 23, 2019 | NCT04098198 | Biomarkers for Inborn Errors of Metabolism | CENTOGENE GmbH Rostock | Observational | Completed | Inborn Errors of Metabolism, Biomarker | 462 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04098198) |
| September 20, 2019 | NCT04097275 | Induced Pluripotent Stem Cells for the Development of Novel Drug Therapies for Inborn Errors of Metabolism (iPSC-IEM) | CENTOGENE GmbH Rostock | Observational | Unknown | Inborn Errors of Metabolism | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04097275) |
| September 16, 2019 | NCT04091113 | Hereditary Angioedema Kininogen Assay | CENTOGENE GmbH Rostock | Observational | Terminated | Hereditary Angioedema | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04091113) |
| March 21, 2019 | NCT03883750 | Induced Pluripotent Stem Cells for Niemann Pick Disease | CENTOGENE GmbH Rostock | Observational | Completed | Niemann-Pick Diseases | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03883750) |
| March 13, 2019 | NCT03872713 | Establishment of Human Cellular Disease Models for Morquio Disease | CENTOGENE GmbH Rostock | Observational | Completed | Morquio Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03872713) |
| March 12, 2019 | NCT03871790 | Peptide-based Immunization for Colon- and and Pancreas-carcinoma | CENTOGENE GmbH Rostock | Observational | Completed | Colon Neoplasm, Colon Adenocarcinoma, Colon Cancer, Colo-rectal Cancer, Rectal Cancer, Rectal Neoplasms, Rectal... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03871790) |
| March 8, 2019 | NCT03867526 | Establishment of Human Cellular Disease Models for Wilson Disease | CENTOGENE GmbH Rostock | Observational | Completed | Wilson Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03867526) |
| March 7, 2019 | NCT03866603 | Rostock International Parkinson's Disease Study (ROPAD) | CENTOGENE GmbH Rostock | Observational | Completed | Parkinson´s Disease | 20,112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03866603) |
| March 7, 2019 | NCT03866590 | Pyruvate Kinase Deficiency Epidemiological Study (PIECE) | CENTOGENE GmbH Rostock | Observational | Completed | Pyruvate Kinase Deficiency | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03866590) |
| August 29, 2018 | NCT03651245 | European Alpha-Mannosidosis Participant | CENTOGENE GmbH Rostock | Observational | Terminated | Immunodeficiency, Skeletal Abnormalities, Deafness, Mental Retardation, Gingival Hypertrophy, Facial Dysmorphism | 667 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03651245) |
| June 15, 2018 | NCT03558009 | Epidemiological Analysis for Hereditary Angioedema Disease | CENTOGENE GmbH Rostock | Observational | Completed | Abdominal Pain, Functional Abdominal Pain | 2,318 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03558009) |
| September 15, 2017 | NCT03284658 | Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 (BioTyrosin) | CENTOGENE GmbH Rostock | Observational | Withdrawn | Tyrosinosis, Hepatorenal Tyrosinemia, Fumarylacetoacetase Deficiency, Fah Deficiency, Metabolic Disorders | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03284658) |
| August 28, 2017 | NCT03264040 | Biomarker for Mannosidosis Disease (BioMannosidosis) | CENTOGENE GmbH Rostock | Observational | Withdrawn | Alpha-Mannosidase B Deficiency, Lysosomal Alpha B Mannosidosis, Alpha-Mannosidase Deficiency | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03264040) |
| August 2, 2017 | NCT03237494 | TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects | CENTOGENE GmbH Rostock | Observational | Completed | Transthyretin Amyloidosis, Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR)... | 5,028 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03237494) |
| June 26, 2017 | NCT03198897 | Biomarker for Homozygous Familial Hypercholesterolemia (BioHoFH) | CENTOGENE GmbH Rostock | Observational | Withdrawn | Lipoprotein Lipase Deficiency, Inborn Error of Lipid Metabolism, Corneal Arcus | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03198897) |
| June 22, 2017 | NCT03196115 | Biomarker for Hyaline Fibromatosis Syndrome (BioHFS) | CENTOGENE GmbH Rostock | Observational | Withdrawn | Hyalinosis, Hyaline Membrane Disease, Juvenile Hyaline Fibromatosis, Fibromatosis Hyalinica Multiplex Juvenilis, Skin... | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03196115) |
| January 24, 2017 | NCT03029728 | Biomarker for Hereditary AngioEdema Disease | CENTOGENE GmbH Rostock | Observational | Completed | C1 Esterase Inhibitor Deficiency, Angio Edema, C4 Deficiency, HAE, Hereditary Angioedema, Hereditary Angioedema Type... | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03029728) |
| December 15, 2016 | NCT02994030 | Biomarker for Duchenne Muscular Dystrophy | CENTOGENE GmbH Rostock | Observational | Completed | Increased Lordosis/Scoliosis, Hyporeflexia, Duchenne Muscular Dystrophy, Red-Green Color Blindness, Lordosis... | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02994030) |
| October 17, 2016 | NCT02934854 | Biomarker for Creatine Deficiency Syndromes (BioCDS) | CENTOGENE GmbH Rostock | Observational | Withdrawn | Intellectual Disability, Developmental Delay, Movement Disorder, Behavioral Disorder, Intractable Epilepsy | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02934854) |

## By phase

| Phase | Trials |
| --- | --- |
| Observational | 57 |

## By status

| Status | Trials |
| --- | --- |
| Withdrawn | 27 |
| Completed | 21 |
| Terminated | 6 |
| Unknown | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Lysosomal Storage Diseases | 6 |
| Fabry Disease | 6 |
| Intellectual Disability | 4 |
| Genetic Diseases, Inborn | 3 |
| Metabolic Diseases | 3 |
| Gaucher Disease | 3 |
| Hepatomegaly | 3 |
| Splenomegaly | 3 |
| Muscle Weakness | 3 |
| Angioedemas, Hereditary | 3 |
| Amyloid Neuropathies, Familial | 3 |
| Stroke | 3 |
| Learning Disabilities | 3 |
| Metabolism, Inborn Errors | 3 |
| Niemann-Pick Diseases | 2 |
| Lipidoses | 2 |
| Lipid Metabolism Disorders | 2 |
| Lipid Metabolism, Inborn Errors | 2 |
| Peripheral Nervous System Diseases | 2 |
| Hereditary Angioedema Types I and II | 2 |
| Amyloidosis, Hereditary, Transthyretin-Related | 2 |
| Amyloid Neuropathies | 2 |
| Parkinson Disease | 2 |
| Glycogen Storage Disease Type II | 2 |
| Mucopolysaccharidosis IV | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Private jet charter companies in the United States](https://specstream.ai/data/businesses/private-jet-charter-companies/united-states)
- [Pulmonology practices in the United States](https://specstream.ai/data/businesses/pulmonology-practices/united-states)
- [Road contractors in the United States](https://specstream.ai/data/businesses/road-contractors/united-states)
- [Sheet metal fabricators in the United States](https://specstream.ai/data/businesses/sheet-metal-fabricators/united-states)
- [Specialty schools in the United States](https://specstream.ai/data/businesses/specialty-schools/united-states)
- [Syrian restaurants in the United States](https://specstream.ai/data/businesses/syrian-restaurants/united-states)
